澳华内镜(688212) - 投资者关系活动记录表2024年5月9日

Group 1: Financial Performance - In Q1 2024, the company's revenue reached 169 million CNY, representing a year-on-year growth of 34.91% [1] - The net profit attributable to shareholders was 2.76 million CNY, a decrease of 83.32% year-on-year [1] - After excluding the impact of share-based payments, the net profit attributable to shareholders was 24.56 million CNY, reflecting a growth rate of 24.15% compared to the same period last year [1] Group 2: Product Development and Market Strategy - The AQ-300 product was launched at the end of 2022 and has undergone market promotion and performance upgrades in 2023, following an S-curve adoption pattern [2] - The company has obtained EU certification for the AQ-300 product and is actively participating in industry conferences to enhance market presence [2] - Future strategies include expanding the AQ-300 series with more models and enhancing brand recognition through academic exchanges and training sessions [2] Group 3: Market Expansion and Challenges - Europe is a key area for the company's overseas business, with ongoing efforts to penetrate cost-effective markets that still have unmet demand for soft endoscopes [2] - The company aims to focus on technological innovation and brand building in the soft endoscope sector, where domestic brands currently hold a low market share [3] - Increasing the penetration rate of gastrointestinal endoscopies in grassroots healthcare requires collaborative efforts, including government support, training systems, and public health awareness campaigns [3]